Dr Marianne Brodmann (Professor of Vascular Medicine, Medical University of Graz, Graz, Austria) discusses the challenges, treatment and developments in antithrombotic therapy in patients with lower extremity arterial disease (LEAD).
Filmed at ESC 2018, Munich.
View more content here.
Speaker Disclosure: Dr Marianne Brodmann has nothing to disclose in relation to this video interview.
1. Please describe the current challenges of treating lower extremity arterial disease (LEAD) compared with other forms of atherosclerotic cardiovascular disease? (0:09)
2. How do you currently treat patients with LEAD? (1:32)
3. What are the treatment goals for patients receiving antithrombotic therapy to treat LEAD? (2:29)
4. What recent developments have there been in the treatment of LEAD, particularly concerning the use of antithrombotic therapy? (3:13)
5. What further research is currently ongoing and planned to assess the benefit of antithrombotic therapy in LEAD? (4:09)
touchCARDIO.com is an independent information resource supporting physicians, clinicians and leading industry professionals in continuously developing their knowledge, effectiveness and productivity, via open-access content in multimedia formats.
Share this Video
Related Videos In Cardiovascular Disease
Zsolt Piroth, TCT 2022: The value of post-PCI FFR and intravascular imaging for cardiovascular failure, a FAME 3 substudy
This FAME 3 substudy aimed to define the value of post-percutaneous coronary intervention (PCI) fractional flow reserve (FFR) and intravascular imaging for cardiovascular failure. In this touchCARDIO interview, we speak with Dr Zsolt Piroth (Gottsegen National Cardiovascular Institute, Budapest, Hungary) to discuss the substudy of the FAME 3 trial and the implications for clinical practice. […]
Zsolt Piroth, TCT 2022: The value of measuring post-PCI FFR in patients with coronary artery disease
The impact of post-percutaneous coronary intervention (PCI) fractional flow reserve (FFR) has been assessed in patients with coronary artery disease (CAD). In this touchCARDIO interview, we speak with Dr Zsolt Piroth (Gottsegen National Cardiovascular Institute, Budapest, Hungary) to discuss the prognostic value for measuring post-PCI FFR and intravascular imaging in CAD. Click here for part […]
Divaka Perera, ESC 2022: Percutaneous revascularisation in patients with severe ischaemic cardiomyopathy, the REVIVED trial
The REVIVED study aimed to assess whether the addition of stents when treating patients with severe ischaemic cardiomyopathy would be beneficial to patient outcomes. In this touchCARDIO interview, we speak with Professor Divaka Perera (King’s College London, London, UK) to discuss the REVIVED trial, its outcomes and how they will affect the current treatment paradigm. […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!